• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Neuroprotective agent in sight?

Article

A neuroprotective approach to the treatment of glaucoma is not imminent, but several promising approaches are under investigation.

Durham, NC-A neuroprotective approach to the treatment of glaucoma is not imminent, but several promising approaches are under investigation. Areas that hold the most possibility are targeting amyloid-beta, complement activation, and tumor necrosis factor (TNF)-alpha signaling, said Stuart J. McKinnon, MD, PhD.

"Will we have one in our lifetime? I hope so," he added. Dr. McKinnon reviewed several therapeutic strategies that have been successful using animal glaucoma models.

This finding suggests a possible relationship between the two diseases, Dr. McKinnon said. Altered metabolism of amyloid-beta and amyloid precursor protein (APP), which plays a central role in neuronal homeostasis, contributes to apoptosis of retinal ganglion cells (RGC) in glaucoma.

Two classes of drugs are FDA-approved to treat AD: acetylcholine esterase inhibitors (donepezil [Aricept, Pfizer/Eisai], rivastigmine [Exelon, Novartis] and galantamine [Razadyne, Ortho-McNeil-Janssen Pharmaceuticals]), and an N-methyl-D-aspartate receptor antagonist, memantine (Namenda, Forest Pharmaceuticals).

In a rat glaucoma model, galantamine was more neuroprotective than donepezil or memantine, Dr. McKinnon said, but memantine did not show any improvement in glaucoma in a large multicenter clinical trial.

Two anti-amyloid approaches that may be useful in the treatment of glaucoma are decreasing amyloid-beta production by secretase inhibition or interfering with amyloid-beta aggregation by using amyloid-beta vaccination. Another strategy that has demonstrated neuroprotection in a rat glaucoma model is the use of intravitreal antibodies to amyloid-beta, Congo red, and beta-secretase inhibitors, singly or in combination.

Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
Katherine Talcott, MD, presenting slides
Katherine Talcott, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.